Thalidomide for the treatment of patients with myelodysplastic syndromes

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al. · Blood · 1997 · 4.4K citations · Full text

Proposals for the classification of the myelodysplastic syndromes

John M. Bennett, Daniel Catovsky, MT Daniel et al. · British Journal of Haematology · 1982 · 3.7K citations

Hematological Malignancy, Hematology, Diagnosis +6

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Seema Singhal, Jayesh Mehta, Raman Desikan et al. · New England Journal of Medicine · 1999 · 2.6K citations · Full text

Thalidomide is an inhibitor of angiogenesis.

Robert J. D’Amato, Michael Loughnan, Evelyn Flynn et al. · Proceedings of the National Academy of Sciences · 1994 · 2.5K citations · Full text

Angiogenesis, Developmental Biology, Ophthalmology +13

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Bruce D. Cheson, John M. Bennett, Hagop M. Kantarjian et al. · PubMed · 2000 · 665 citations